Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Archive ouverte

Schuepbach, W.M. Michael | Tonder, Lisa | Schnitzler, Alfons | Krack, Paul | Rau, Joern | Hartmann, Andreas | Hälbig, Thomas | Pineau, Fanny | Falk, Andrea | Paschen, Laura | Paschen, Stephen | Volkmann, Jens | Dafsari, Haidar | Barbe, Michael | Fink, Gereon | Kühn, Andrea | Kupsch, Andreas | Schneider, Gerd-H. | Seigneuret, Eric | Fraix, Valérie | Kistner, Andrea | Chaynes, P. Patrick | Ory-Magne, Fabienne | Brefel-Courbon, Christine | Vesper, Jan | Wojtecki, Lars | Derrey, Stéphane | Maltête, David | Damier, Philippe | Derkinderen, Pascal | Sixel-Döring, Friederike | Trenkwalder, Claudia | Gharabaghi, Alireza | Wächter, Tobias | Weiss, Daniel | Pinsker, Marcus, O. | Regis, Jean-Marie | Witjas, Tatiana | Thobois, Stéphane | Mertens, Patrick | Knudsen, Karina | Schade-Brittinger, Carmen | Houeto, Jean-Luc | Agid, Yves | Vidailhet, Marie | Timmermann, Lars | Deuschl, Günther

Edité par CCSD ; American Academy of Neurology -

International audience. ObjectiveTo investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation(DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.MethodsWe performed a secondary analysis of data from the previously published EARLYSTIM study, a prospectiverandomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-upwith disease-specific QOL (39-item Parkinson’s Disease Questionnaire summary index [PDQ-39-SI]) as theprimary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration ofmotor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease RatingScale (UPDRS) (UPDRS-III“off”and “on” medications, UPDRS-IV) were conducted to determine predictorsof change in PDQ-39-SI.ResultsPDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups(p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months.No correlation was found for any of the other baseline characteristics analyzed in either treatment group.ConclusionImpaired QOL as subjectively evaluated by the patient is the most important predictor of benefit inpatients with PD and early motor complications, fulfilling objective gold standard inclusion criteria forSTN-DBS. Our results prompt systematically including evaluation of disease-specific QOL whenselecting patients with PD for STN-DBS.

Consulter en ligne

Suggestions

Du même auteur

Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Archive ouverte | Lhommée, Eugénie | CCSD

International audience

Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson's Disease

Archive ouverte | Pinto, Serge | CCSD

International audience. Background: The EARLYSTIM trial demonstrated for Parkinson ’ s disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN-DBS) and best medica...

Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications

Archive ouverte | Barbe, Michael | CCSD

International audience. Background Effects of DBS on freezing of gait and other axial signs in PD patients are unclear. Objective Secondary analysis to assess whether DBS affects these symptoms within a large random...

Chargement des enrichissements...